Efficacy and adverse effects of medications used in the treatment of glaucoma

Carl B. Camras, Carol B Toris, Richard R. Tamesis

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

With the advent of several new topically active medications for glaucoma therapy, intraocular pressure (IOP) can be reduced to target levels in more patients before resorting to surgery. Some of these newer agents have a number of advantages over some of the older medications, several of which are seldom used now. The topically active carbonic anhydrase inhibitors are better tolerated than oral formulations, which are infrequently used despite their greater efficacy compared with the topical formulations. The α2-adrenergic agonists effectively reduce IOP with few systemic adverse effects. The prostaglandin analogues are even more effective and well tolerated when applied once daily without known systemic adverse effects. The variety of glaucoma medications forces the physician to be selective with various combinations before proceeding with surgery. This article critically reviews the literature pertaining to the newer glaucoma medications, thereby providing guidelines to make rational choices from among the available options.

Original languageEnglish (US)
Pages (from-to)377-388
Number of pages12
JournalDrugs and Aging
Volume15
Issue number5
DOIs
StatePublished - Nov 22 1999

Fingerprint

Glaucoma
Intraocular Pressure
Carbonic Anhydrase Inhibitors
Synthetic Prostaglandins
Adrenergic Agonists
Therapeutics
Guidelines
Physicians

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

Efficacy and adverse effects of medications used in the treatment of glaucoma. / Camras, Carl B.; Toris, Carol B; Tamesis, Richard R.

In: Drugs and Aging, Vol. 15, No. 5, 22.11.1999, p. 377-388.

Research output: Contribution to journalReview article

Camras, Carl B. ; Toris, Carol B ; Tamesis, Richard R. / Efficacy and adverse effects of medications used in the treatment of glaucoma. In: Drugs and Aging. 1999 ; Vol. 15, No. 5. pp. 377-388.
@article{2d3ac767705d4ae08b4545fcea3c9d02,
title = "Efficacy and adverse effects of medications used in the treatment of glaucoma",
abstract = "With the advent of several new topically active medications for glaucoma therapy, intraocular pressure (IOP) can be reduced to target levels in more patients before resorting to surgery. Some of these newer agents have a number of advantages over some of the older medications, several of which are seldom used now. The topically active carbonic anhydrase inhibitors are better tolerated than oral formulations, which are infrequently used despite their greater efficacy compared with the topical formulations. The α2-adrenergic agonists effectively reduce IOP with few systemic adverse effects. The prostaglandin analogues are even more effective and well tolerated when applied once daily without known systemic adverse effects. The variety of glaucoma medications forces the physician to be selective with various combinations before proceeding with surgery. This article critically reviews the literature pertaining to the newer glaucoma medications, thereby providing guidelines to make rational choices from among the available options.",
author = "Camras, {Carl B.} and Toris, {Carol B} and Tamesis, {Richard R.}",
year = "1999",
month = "11",
day = "22",
doi = "10.2165/00002512-199915050-00005",
language = "English (US)",
volume = "15",
pages = "377--388",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Efficacy and adverse effects of medications used in the treatment of glaucoma

AU - Camras, Carl B.

AU - Toris, Carol B

AU - Tamesis, Richard R.

PY - 1999/11/22

Y1 - 1999/11/22

N2 - With the advent of several new topically active medications for glaucoma therapy, intraocular pressure (IOP) can be reduced to target levels in more patients before resorting to surgery. Some of these newer agents have a number of advantages over some of the older medications, several of which are seldom used now. The topically active carbonic anhydrase inhibitors are better tolerated than oral formulations, which are infrequently used despite their greater efficacy compared with the topical formulations. The α2-adrenergic agonists effectively reduce IOP with few systemic adverse effects. The prostaglandin analogues are even more effective and well tolerated when applied once daily without known systemic adverse effects. The variety of glaucoma medications forces the physician to be selective with various combinations before proceeding with surgery. This article critically reviews the literature pertaining to the newer glaucoma medications, thereby providing guidelines to make rational choices from among the available options.

AB - With the advent of several new topically active medications for glaucoma therapy, intraocular pressure (IOP) can be reduced to target levels in more patients before resorting to surgery. Some of these newer agents have a number of advantages over some of the older medications, several of which are seldom used now. The topically active carbonic anhydrase inhibitors are better tolerated than oral formulations, which are infrequently used despite their greater efficacy compared with the topical formulations. The α2-adrenergic agonists effectively reduce IOP with few systemic adverse effects. The prostaglandin analogues are even more effective and well tolerated when applied once daily without known systemic adverse effects. The variety of glaucoma medications forces the physician to be selective with various combinations before proceeding with surgery. This article critically reviews the literature pertaining to the newer glaucoma medications, thereby providing guidelines to make rational choices from among the available options.

UR - http://www.scopus.com/inward/record.url?scp=0032745199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032745199&partnerID=8YFLogxK

U2 - 10.2165/00002512-199915050-00005

DO - 10.2165/00002512-199915050-00005

M3 - Review article

C2 - 10600045

AN - SCOPUS:0032745199

VL - 15

SP - 377

EP - 388

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 5

ER -